Longeveron Inc. (LGVN)

Longeveron Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Longeveron Inc. (LGVN) is a Biotechnology company based in US with a market capitalization of $15.4M. Revenue declined 49.9% year-over-year and free cash flow was negative at -$18.9M. This page tracks LGVN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 25 employees · IPO Feb 12, 2021

Valuation

Valuation & price

$0.67as of May 17, 2026· -61.5% vs 52w high

P/E ratio

Latest-FY diluted EPS

2.72

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$1.74$1.11$0.48Jul 25Dec 25Jul 26
$0.4852-week range$1.74
Loading valuation history…

Fundamentals

Key fundamentals

$15.4M

Market cap

-49.9%

Revenue growth (YoY)

67.0%

Gross margin

-$18.9M

Free cash flow (USD)

-$3.8M

Net debt

Net cash position

18.0%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20182025

$2.1M$1.2M

Free cash flow by year

20182025

-$5.4M-$18.9M

Gross margin by year

20212025

45.2%67.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJun 5, 2026Filing

    CFO Departure

  • Quarterly reportMay 13, 2026Filing

    10-Q Filed

  • 8-K eventMay 13, 2026Filing

    Earnings Release

  • 8-K eventMay 8, 2026Filing

    FDA Meeting Summary

  • 8-K eventApr 10, 2026Filing

    Executive Compensation Adjustment

Questions

Frequently asked questions

What is Longeveron Inc.'s market cap?

Longeveron Inc. (LGVN) has a market capitalization of $15.4M.

What is LGVN's P/E ratio?

A meaningful P/E ratio is not available for LGVN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is LGVN's price-to-book (P/B) ratio?

LGVN trades at 2.72 times book value per share.

Are insiders buying LGVN stock?

SEC Form 4 filings show no open-market insider buys at Longeveron Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.